- Kymera Therapeutics, Inc. (NASDAQ:KYMR) announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data Review Committee, Sanofi (NASDAQ:SNY) has informed Kymera that it intends to expand the ongoing Hidradenitis Suppurativa and Atopic Dermatitis Phase 2 trials to more rapidly progress towards pivotal studies.
- KYMR has risen 36.76% in the last 12 months.
- Source: Press Release